GenFleet Therapeutics (Shanghai) (HKG:2595) said GFH375 was granted the breakthrough therapy designation in China as a treatment for a type of non-small cell lung cancer, according to a Hong Kong bourse filing Monday.
The company is studying the medicine in patients with KRAS G12D-mutant non-small cell lung cancer patients who have received at least one prior systemic therapy.
The company expects to announce data from ongoing studies of the medicine at global academic events this year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments